3Nisssen SE. High-dose statins in acute coronary syndromes. Not just lipid levels JAMA, 2004,1292,1365-1367.
4Henst protection study, collaborative Group. MRC/BHF Heart protection study of cholesterol lowering with simvastation in 20536 high-risk individuals: a randomized placebo-contrdled trial. Lancet, 2002,360:7-22.
5expert panel on Detection. Evaluation and Treatment of High Blood cholesterolin Adults. Excutive Summary of the Third peport of the National cholesterol Education Program (IVCEP) Expert pane/on Detection, Evaluation,and Treatment of High Blood cholesterol in Aolult (atp Ⅲ).JAM ,2001,19:2486-2497.
6Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastain on early recurrent ischemic events in acute ccoronary syndromes:the MIRACLE study. Arandomized controlledtrial. JAMA, 2001,285: 1711-1718.
7cannon CP,I Braunwald E, Mclade C, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndrome. N Engl J Med,2004,350 : 1495-1504.
8Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease, application to clinical and public health practice:a statement for healthcare profession from the centers for disease control and prevention and the American Heart Associalion. Circulation,2003,107:499-512.
9The Long-Term Intervention with pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and broad range of initial cholesterol levels. New Eng J Med 1998;339:1349- 1357.
10Keech A, Colguhoun D, Best J, et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose, Diabetes Care 2003 ;26:2713 - 2721.
